Sanofi: Lymphoma trials
The registry lists 17 Lymphoma studies with Sanofi as lead sponsor. 0 are open to participants now and 2 have results posted.
Phase 1 4Phase 2 7Phase 3 2Phase 4 2No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Isatuximab-based Therapy in Participants With LymphomaTerminatedNCT03769181Phase 1/2Results posted
- Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis SyndromeCompletedNCT00230178Phase 3Results posted
- Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute LeukemiaCompletedNCT04349306Phase 4
- Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin LymphomaCompletedNCT02221492Phase 2
- Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous TransplantationCompletedNCT01738373
- A Study of Investigational SAR245409 in Patients With Certain Lymphoma or LeukemiaCompletedNCT01403636Phase 2
- Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of PlerixaforCompletedNCT01362985
- Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving PlerixaforCompletedNCT01362972
- A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).CompletedNCT00838357Phase 3
- SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's LymphomaCompletedNCT00796731Phase 1
- Fludara (Oral) Phase II Study for Indolent LymphomaCompletedNCT00688883Phase 2
- Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
- Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or LymphomaCompletedNCT00631579Phase 2
- Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's LymphomaCompletedNCT00549185Phase 1
- Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or LymphomaCompletedNCT00486135Phase 1
- Rasburicase for HyperuricemiaCompletedNCT00290992Phase 2
- Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor MalignancyCompletedNCT00230217Phase 4